There are 2185 resources available
996MO - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation
Presenter: Jason Luke
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
LBA71 - Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)
Presenter: Vincenza Conteduca
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
LBA11 - Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
Presenter: Iris Nederlof
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
CN15 - Mobile application-based intervention study in improving treatment adherence and quality of life in cancer patients
Presenter: Gunisetty Prakash
Session: eHealth and digital innovations
Resources:
Abstract
997MO - A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01
Presenter: Joanne Lundy
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
LBA13 - Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial
Presenter: Peter A. Fasching
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
998MO - Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study
Presenter: Oliver Klein
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
1597MO - Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dana Rathkopf
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
LBA72 - Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niven Mehra
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
999MO - HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma
Presenter: Christian Ottensmeier
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract